Neurocrine biosciences announces fda approval of ingrezza® (valbenazine) capsules for the treatment of chorea associated with huntington's disease
San diego , aug. 18, 2023 /prnewswire/ -- neurocrine biosciences, inc . (nasdaq: nbix) today announced the u.s. food and drug administration (fda) has approved ingrezza® (valbenazine) capsules for the treatment of adults with chorea associated with huntington's disease (hd).1 ingrezza is the only selective vesicular monoamine transporter 2 (vmat2) inhibitor that offers an effective starting dosage that can be adjusted by a patient's healthcare provider based on response and tolerability, with no complex titration.1 only ingrezza offers simple dosing that is always one capsule, once daily.1 experience the full interactive multichannel news release here: https://www.multivu.com/players/english/9147451-neurocrine-biosciences-fda-approval-ingrezza/ the fda approval is supported by data from two clinical studies conducted in collaboration with the huntington study group (hsg), including the kinect®-hd phase 3 study and the ongoing kinect®-hd2 open-label extension trial.1,2 kinect-hd, a randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of ingrezza, met its primary endpoint of least squares mean (lsm) change in chorea severity using the total maximal chorea (tmc) score of the unified huntington's disease rating scale (uhdrs) from screening period baseline to maintenance period (average of weeks 10 and 12), demonstrating a statistically significant greater improvement in tmc score with ingrezza versus placebo.1,2 "we are proud to bring ingrezza to people living with hd and their caregivers who now have the option of a one-capsule, once-daily treatment that has demonstrated significant improvement in hd chorea in clinical studies," said kevin c.
NBIX Ratings Summary
NBIX Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission